logo image
search icon
GLP-1 Agonists Market

GLP-1 Agonists Market Size, Share & Trends Analysis Report By Route of Administration (Oral, Injection), By Molecule (Dulaglutide, Liraglutide, Semaglutide, Lixisenatide, Exenatide, Tirzepatide), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Region And Segment Forecasts, 2023-2031

Report ID : 2289 | Published : 2023-12-19 | Pages: 180 | Format: PDF/EXCEL

GLP-1 Agonists Market Size is valued at USD 4.07 billion in 2022 and is predicted to reach USD 10.32 billion by the year 2031 at a 11.3% CAGR during the forecast period for 2023-2031.

GLP-1 Agonists Market

GLP-1 agonists, known to be beneficial in treating type 2 diabetes, are glucagon-like peptide-1 receptor agonists. The action of GLP-1 RAs is to enhance insulin synthesis and inhibit glucagon secretion by activating GLP-1 receptors. While all GLP-1 RAs have the exact mechanism of action, there are differences in formulation, dose, injection technique, and administration. The considerable cardiovascular benefits associated with specific GLP-1 agonists and the well-documented efficacy of GLP-1 agonists in diabetes care are two key drivers driving this industry ahead. These drugs help manage type 2 diabetes by increasing insulin production and decreasing glucagon release, improving blood sugar control and cardiovascular health. GLP-1 agonists have demonstrated potential in managing weight, a crucial motivation. Because type 2 diabetes and obesity are frequently co-occurring, this technique is very helpful in managing both conditions. Because these drugs lead to weight loss, they appeal to patients and doctors. Furthermore, developing new treatments is anticipated to fuel the growth of the GLP-1 receptor agonist market.

However, the market development is hampered by the high-cost criteria for the safety and health of the GLP-1 agonists market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high GLP-1 agonists because GLP-1 agonists are expensive, which can prevent some patients from getting the treatment they need. There may not be extensive use due to this financial obstacle and worries about injections. There may not be extensive use due to this financial obstacle and worries about injections. One potential future hurdle for the growth of the market for glucagon-like peptide 1 (GLP-1) agonists is the availability of suitable insurance. As a result of COVID-19-related travel restrictions and lockdowns, the worldwide supply chain for GLP-1 receptor agonists was disrupted. Because of this, the healthcare business was hit hard by the COVID-19 pandemic, which disrupted the supply chain and compromised processes ranging from ingredient procurement to final delivery.

Competitive Landscape

Some of the major key players in the GLP-1 agonists market are:

  • Eli Lilly and Company
  • Sanofi
  • AstraZeneca
  • Novo Nordisk
  • Boehringer Ingelheim
  • Twist Bioscience Corporation

Market Segmentation:

The GLP-1 agonists market is segmented based on route of administration, molecule, and distribution channel. The route of administration segment includes oral and injection. By molecule, the market is segmented into dulaglutide, liraglutide, semaglutide, lixisenatide, exenatide, and tirzepatide. Distribution channel includes hospital pharmacies, retail pharmacies, and others.

Based On The Molecule, The Dulaglutide GLP-1 Agonists Market Segment Is Accounted As A Major Contributor To The GLP-1 Agonists Market

The dulaglutide GLP-1 agonists market is expected to have a significant global market share in 2022. Combining dulaglutide with dietary and physical activity changes can aid blood sugar control. In addition to lowering the risk of death, heart attack, and stroke, this drug also reduces the risk of these complications in diabetic individuals.

Retail Pharmacies Segment To Witness Growth At A Rapid Rate

Retail pharmacies make up the bulk of GLP-1 agonists usage because participating in retail pharmacies in clinical trials provides more individualized patient care. As the initial point of contact for many patients seeking medical assistance, retail pharmacists can be crucial in identifying individuals suited for clinical trials, particularly in nations like the US, Germany, the UK, China, and India.

The North American GLP-1 Agonists Market Holds A Significant Revenue Share In The Region.

The North American GLP-1 agonists market is expected to register the highest market share in revenue in the near future. The area has a well-developed healthcare infrastructure, major actors are present, the disease prevalence is high, and investments in research and development for novel medications to treat diabetes and obesity are expanding. In addition, Asia Pacific is projected to increase in the global GLP-1 agonists market because diabetes and other linked illnesses are becoming more common. With more generic pharmaceuticals hitting the market, the glucagon-like peptide 1 (GLP-1) agonists market is expected to develop in the region.

GLP-1 Agonists Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2022

USD 4.07 Bn

Revenue Forecast In 2031

USD 10.32 Bn

Growth Rate CAGR

CAGR of 11.3 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Route Of Administration, Molecule, And Distribution Channel

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Competitive Landscape

Eli Lilly and Company, Sanofi, AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and Twist Bioscience Corporation

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global GLP-1 Agonists Market Snapshot

Chapter 4. Global GLP-1 Agonists Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Route of Administration Estimates & Trend Analysis

5.1. By Route of Administration, & Market Share, 2020 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Route of Administration:

5.2.1. Oral

5.2.2. Injection

Chapter 6. Market Segmentation 2: By Molecule Estimates & Trend Analysis

6.1. By Molecule & Market Share, 2020 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Molecule:

6.2.1. Dulaglutide

6.2.2. Liraglutide

6.2.3. Semaglutide

6.2.4. Lixisenatide

6.2.5. Exenatide

6.2.6. Tirzepatide

Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis

7.1. By Distribution Channel & Market Share, 2020 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Distribution Channel:

7.2.1. Hospital Pharmacies

7.2.2. Retail Pharmacies

7.2.3. Others

Chapter 8. GLP-1 Agonists Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America GLP-1 Agonists Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031

8.1.2. North America GLP-1 Agonists Market revenue (US$ Million) estimates and forecasts By Molecule, 2019-2031

8.1.3. North America GLP-1 Agonists Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031

8.1.4. North America GLP-1 Agonists Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

8.2. Europe

8.2.1. Europe GLP-1 Agonists Market revenue (US$ Million) By Route of Administration, 2019-2031

8.2.2. Europe GLP-1 Agonists Market revenue (US$ Million) By Molecule, 2019-2031

8.2.3. Europe GLP-1 Agonists Market revenue (US$ Million) By Distribution Channel, 2019-2031

8.2.4. Europe GLP-1 Agonists Market revenue (US$ Million) by country, 2019-2031

8.3. Asia Pacific

8.3.1. Asia Pacific GLP-1 Agonists Market revenue (US$ Million) By Route of Administration, 2019-2031

8.3.2. Asia Pacific GLP-1 Agonists Market revenue (US$ Million) By Molecule, 2019-2031

8.3.3. Asia Pacific GLP-1 Agonists Market revenue (US$ Million) By Distribution Channel, 2019-2031

8.3.4. Asia Pacific GLP-1 Agonists Market revenue (US$ Million) by country, 2019-2031

8.4. Latin America

8.4.1. Latin America GLP-1 Agonists Market revenue (US$ Million) By Route of Administration, (US$ Million) 2019-2031

8.4.2. Latin America GLP-1 Agonists Market revenue (US$ Million) By Molecule, (US$ Million) 2019-2031

8.4.3. Latin America GLP-1 Agonists Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031

8.4.4. Latin America GLP-1 Agonists Market revenue (US$ Million) by country, 2019-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa GLP-1 Agonists Market revenue (US$ Million) By Route of Administration, (US$ Million) 2019-2031

8.5.2. Middle East & Africa GLP-1 Agonists Market revenue (US$ Million) By Molecule, (US$ Million) 2019-2031

8.5.3. Middle East & Africa GLP-1 Agonists Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031

8.5.4. Middle East & Africa GLP-1 Agonists Market revenue (US$ Million) by country, 2019-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Eli Lilly and Company

9.2.2. Sanofi

9.2.3. AstraZeneca

9.2.4. Novo Nordisk

9.2.5. Boehringer Ingelheim

9.2.6. Twist Bioscience Corporation

Segmentation of GLP-1 Agonists Market-

By Route of Administration-

  • Oral
  • Injection

GLP-1 Agonists Market Seg

By Molecule-

  • Dulaglutide
  • Liraglutide
  • Semaglutide
  • Lixisenatide
  • Exenatide
  • Tirzepatide

By Distribution Channel-

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the GLP-1 Agonists Market Size?

GLP-1 Agonists Market is expected to grow at a 11.3% CAGR during the forecast period for 2023-2031.

Eli Lilly and Company, Sanofi, AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and Twist Bioscience Corporation

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach